WHO adds new drugs to COVID treatment within Omicron surgery | Coronavirus Plague News
[ad_1]
Recent ideas are promoting a new patent application for more people to receive treatment.
The World Health Organization (WHO) has added two additional drugs to its recommended drug regimen to COVID-19, since Omicron’s highly contagious form of coronavirus triggers unprecedented surgeries worldwide.
The drug baricitinib, which is also used in the treatment of rheumatoid arthritis, is “recommended” for patients with severe or severe COVID-19, in combination with corticosteroids, a group of UN experts stated in guidelines published by Britain. Medical Journal.
The drug reduces the need for oxygen and has been found to improve patients’ chances of survival without any signs of increased complications, the team said.
The team also provided a “legal recommendation” for sotrovimab, a test monoclonal antibody, for those who do not have COVID-19 but who are at high risk of being admitted to the hospital. Monoclonal antibodies are lab-based drugs that mimic the body’s natural defenses.
New treatment guidelines come as the epidemic escalates worldwide. More than 15 million new cases of COVID-19 were reported to the WHO last week – the largest one in a week – led by the Omicron brand, which is replacing Delta almost everywhere.
The recommendation drew on new evidence from seven trials involving more than 4,000 patients with severe, severe and severe cases of COVID-19.
“Recommendations in addition to previous recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids in patients with severe or severe covid-19; approved recommendations for the use of casirivimab-imdevimab (other monoclonal antibody) in selected patients; and against and the use of convalescent plasma, ivermectin and hydroxychloroquine in patients with covid-19 regardless of the risk of infection, “the WHO said in a statement.
The French humanitarian agency Médecins Sans Frontières (MSF) has embraced the new concept and urged governments to implement patent protection to ensure that more people can benefit from the treatment.
Baricitinib is manufactured by the United States drug giant Eli Lilly, and although generic versions are available in India and Bangladesh, patents are valid in many other countries including Brazil and Indonesia.
“For almost two years, we have been seeing people dying with COVID-19 without assistance in the midst of serious illness. In countries where MSF operates,” said Dr Márcio da Fonseca, medical advisor for the MSF Access Campaign.
“The opportunity to provide quality medical care is limited, so saving the lives of many people with serious illnesses and illnesses depends largely on finding the cheapest drugs we can add to the steroids, oxygen and immediate care we already provide. Our services. it would be an insult if they were not found in an uninhabited area, because they are legal and very expensive. ”
WHO added: “life-saving”Interleukin-6 receptor blockers in its COVID-19 regimen last July. Recommended use corticosteroids in September 2020.
In recent weeks, state authorities have also approved a new oral treatment for the disease, including Paxlovid, Pfizer’s. antiviral pill, which showed about 90 percent efficacy in hospitalization and mortality in high-risk patients. It also retained its power with Omicron, the company said.
[ad_2]
Source link